Birmingham research paves the way for new anti-fibrotic therapy for glaucoma
E-Mail Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness. OAG develops slowly over many years. Excessive matrix deposition (fibrosis) within the eye's main fluid drainage site can lead to increased intraocular pressure (IOP), resulting in damage to the optic nerve. 1 The research, reported in npj Regenerative Medicine, has shown that that ILB can normalise...